Krystal Biotech Inc [KRYS] stock is trading at $285.04, up 1.07%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KRYS shares have gain 9.04% over the last week, with a monthly amount glided 19.49%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Krystal Biotech Inc [NASDAQ: KRYS] stock has seen the most recent analyst activity on January 06, 2026, when Citigroup upgraded its rating to a Buy but kept the price target unchanged to $309 for it. Previously, Jefferies started tracking the stock with Buy rating on March 05, 2025, and set its price target to $245. On August 06, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $204 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $160 on November 20, 2023. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $100 as its price target on October 24, 2023. Citigroup started tracking with a Buy rating for this stock on October 12, 2023, and assigned it a price target of $160. In a note dated September 07, 2023, Berenberg initiated an Buy rating and provided a target price of $154 on this stock.
Krystal Biotech Inc [KRYS] stock has fluctuated between $122.80 and $295.98 over the past year. Currently, Wall Street analysts expect the stock to reach $250 within the next 12 months. Krystal Biotech Inc [NASDAQ: KRYS] shares were valued at $285.04 at the most recent close of the market. An investor can expect a potential drop of -12.29% based on the average KRYS price forecast.
Analyzing the KRYS fundamentals
Krystal Biotech Inc [NASDAQ:KRYS] reported sales of 373.16M for the trailing twelve months, which represents a growth of 16.65%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at 0.42%, Pretax Profit Margin comes in at 0.5%, and Net Profit Margin reading is 0.53%. To continue investigating profitability, this company’s Return on Assets is posted at 0.16, Equity is 0.19 and Total Capital is 0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Krystal Biotech Inc’s Current Ratio is 10.14. Further, the Quick Ratio stands at 9.73, while the Cash Ratio is 4.3. Considering the valuation of this stock, the price to sales ratio is 22.15, the price to book ratio is 7.26 and price to earnings (TTM) ratio is 42.75.
Transactions by insiders
Recent insider trading involved Krishnan Suma, President, R&D, that happened on Dec 04 ’25 when 25000.0 shares were sold. President, R&D, Krishnan Suma completed a deal on Dec 04 ’25 to sell 25000.0 shares. Meanwhile, President and CEO Krishnan Krish S sold 25000.0 shares on Dec 04 ’25.
